Compound Profile: Duratia 30 Fortune Health Care
Duratia 30 is a pharmaceutical formulation manufactured by Fortune Health Care containing dapoxetine as the active compound. Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) that has undergone extensive laboratory investigation for its pharmacokinetic profile and receptor binding characteristics. Research facilities worldwide study this compound for its unique absorption and elimination properties compared to conventional SSRIs. The compound demonstrates rapid onset and clearance in pharmacological models, making it valuable for investigating serotonin transporter modulation. Researchers at Stroid UK Shop can examine this formulation’s bioavailability parameters and metabolic pathways in controlled laboratory environments. Scientists investigating serotonin pharmacology often utilise this compound alongside other research tools from our dapoxetine research collection.
Laboratory Applications
Laboratory investigations focus on dapoxetine’s distinctive pharmacological profile, particularly its rapid absorption and short half-life characteristics. Research protocols examine the compound’s interaction with serotonin transporter proteins and downstream signalling pathways. In-vitro studies evaluate cellular uptake mechanisms and metabolite formation patterns. Comparative pharmacokinetic studies analyse absorption rates against longer-acting SSRI compounds. Research teams investigate the compound’s tissue distribution properties and elimination kinetics in experimental models. Studies examine receptor binding affinity and selectivity profiles across various serotonin receptor subtypes. Researchers also evaluate drug-drug interaction potential and enzyme induction effects. The compound serves as a valuable reference standard for laboratories studying rapid-acting serotonin modulators. Research facilities often combine these investigations with studies on compounds from our selective androgen receptor modulator range for comprehensive hormonal pathway research.
Product Specifications
| Parameter | Value |
|---|---|
| Active Compound | Dapoxetine |
| Strength | 30mg per unit |
| Manufacturer | Fortune Health Care |
| Form | Tablet |
| CAS Number | 119356-77-3 |
| Molecular Formula | C₂₁H₂₃NO |
| Molecular Weight | 305.41 g/mol |
| Storage Requirements | Room temperature, dry conditions |
Research Compliance
Duratia 30 research formulations are supplied exclusively for legitimate laboratory research applications. Research facilities must maintain appropriate documentation and storage protocols when investigating this compound’s pharmacological properties. Scientists studying serotonin pathway modulation often incorporate this research tool alongside compounds from our peptide research collection for comprehensive neurotransmitter studies. All investigations must comply with institutional research protocols and regulatory guidelines governing pharmaceutical research compounds.
This product is strictly intended for in-vitro research purposes only and is not approved for human consumption, therapeutic use, or any clinical applications.
